On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...